Vehicle
Indication
Modality
Delivery route
Discovery
Preclinical
Clinical
(Phase 1 and 2)
Liposome
Indication
Breast cancer
Modality
Small molecule
Delivery route
IV
Discovery
Preclinical
Clinical
(Phase 1 and 2)
Indication
Lung cancer
Modality
Small molecule
Delivery route
IV
Discovery
Preclinical
Clinical
(Phase 1 and 2)
Indication
Pancreatic cancer
Modality
Small molecule
Delivery route
IV
Discovery
Preclinical
Clinical
(Phase 1 and 2)
Indication
Infection
Modality
Small molecule
Delivery route
IV
Discovery
Preclinical
Clinical
(Phase 1 and 2)
Indication
Local anesthesia
Modality
Small molecule
Delivery route
Local injection
Discovery
Preclinical
Clinical
(Phase 1 and 2)
Vehicle
Indication
Modality
Delivery route
Vehicle
Preclinical
Clinical
(Phase 1 and 2)
Lipid Nanoparticle
Indication
Viral infection
Modality
mRNA
Delivery route
IM
Discovery
Preclinical
Clinical
(Phase 1 and 2)
Indication
Liver disease
Modality
Cas9 mRNA + SgRNA
Delivery route
IV
Discovery
Preclinical
Clinical
(Phase 1 and 2)
Vehicle
Indication
Modality
Delivery route
Vehicle
Preclinical
Clinical
(Phase 1 and 2)
Nanocrystal
Indication
Mental disorder
Modality
Small molecule
Delivery route
IM
Discovery
Preclinical
Clinical
(Phase 1 and 2)
Multidrug resistance is responsible for over 90% of deaths in cancer patients. Treatment based on drug combinations emerges as a promising method to tackle cancer drug resistance, and drug vehicles that can deliver multiple therapeutic agents at their synergistic ratios to the tumor site are the key to desired treatment efficacy.
However, limited drug delivery systems can be utilized for combined therapeutic agent delivery, and they suffer from unavoidable drawbacks, such as low drug loading content, premature drug leakage and inferior product stability. Our liposome-based drug delivery platform is designed to address this unmet medical need by efficiently encapsulating multiple cancer drug compounds within the same liposome vehicle for synergistic therapeutic effect, and the product exhibits desired physiochemical stability and enhanced therapeutic outcome.
With over 70 million surgeries performed annually in the United States, postoperative pain is a pervasive issue. The prevailing method for achieving extended anesthesia, lasting multiple days, currently relies on catheter techniques employing disposable pumps or multiple injections. These existing treatment modalities confront both technical and clinical challenges, necessitating the exploration of enhanced alternatives. At NanoTech, our dedicated team is committed to developing liposome-based systems designed to facilitate the sustained release of local anesthetic agents, thereby achieving an extended duration of analgesia. Our advanced delivery vehicle is capable of accommodating a substantial drug payload, ensuring a consistently adequate concentration of anesthetic agent at the nerve block site for an extended period. Our primary objective is to offer improved solutions for enhancing postoperative pain management.
With the improved delivery specificity and efficiency, our AccuLNP® platform can carry a variety of genetic cargos to the disease site and has the potential to be applied across a wide range of genetic disorders including central nervous system (CNS), liver, and cancer.
© 2024 NanoTech Pharm Inc. All rights reserved.